AlphaQuest LLC Acquires 7,867 Shares of Immunome, Inc. (NASDAQ:IMNM)

AlphaQuest LLC boosted its holdings in shares of Immunome, Inc. (NASDAQ:IMNM) by 786,700.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,868 shares of the company’s stock after purchasing an additional 7,867 shares during the period. AlphaQuest LLC’s holdings in Immunome were worth $84,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in the stock. Stoneridge Investment Partners LLC bought a new stake in shares of Immunome in the 4th quarter valued at $123,000. Johnson Financial Group LLC purchased a new stake in Immunome during the fourth quarter valued at about $212,000. Intech Investment Management LLC purchased a new stake in shares of Immunome during the third quarter worth $219,000. Raymond James Financial Inc. bought a new position in shares of Immunome in the fourth quarter valued at approximately $274,000. Finally, Three Bridge Wealth Advisors LLC purchased a new stake in Immunome in the 4th quarter worth approximately $293,000. 44.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on IMNM shares. Lifesci Capital initiated coverage on Immunome in a report on Tuesday, March 11th. They issued an “outperform” rating and a $20.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $33.00 price target on shares of Immunome in a research note on Monday, March 10th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, Immunome has a consensus rating of “Buy” and a consensus price target of $27.17.

Immunome Stock Performance

Shares of Immunome stock opened at $8.36 on Wednesday. The stock has a market capitalization of $666.94 million, a PE ratio of -1.03 and a beta of 1.93. Immunome, Inc. has a 52-week low of $8.35 and a 52-week high of $26.70. The company has a 50-day simple moving average of $9.89 and a two-hundred day simple moving average of $11.66.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall purchased 150,000 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were purchased at an average cost of $7.75 per share, for a total transaction of $1,162,500.00. Following the purchase, the chief executive officer now directly owns 669,636 shares in the company, valued at approximately $5,189,679. This represents a 28.87 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 8.60% of the company’s stock.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.